Navigation Links
Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
Date:2/3/2009

Intellectual property based on breakthrough research from a team led by Dr. Jean-Claude Tardif at the Montreal Heart Institute Research Centre, Canada.

TOULOUSE, France and ANN ARBOR, Mich., Feb. 3 /PRNewswire/ -- Cerenis Therapeutics SA (Cerenis), a privately held pharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced that it has in-licensed intellectual property supporting an investigational new treatment of aortic valve stenosis (AVS) based on HDL therapy. This technology is based on the findings of a study led by Jean-Claude Tardif, M.D. at the Montreal Heart Institute Research Centre in Canada.

AVS is characterized by a narrowing of the aortic valve, which can obstruct the flow of oxygenated blood from the heart to the rest of the body. As the heart works harder to compensate for the obstruction, the heart muscle thickens and can cause a potentially dangerous imbalance in blood pressure between the heart and body. Symptoms of severe AVS can include angina and syncope (fainting), and major complications can include heart failure and sudden death. AVS is the most common form of heart valve disease in Western countries, resulting in more than 50,000 aortic valve replacement surgeries each year in the U.S.

In Dr. Tardif's placebo-controlled study in rabbit AVS models, the aortic valve opening in the treatment group returned to a near-normal state and aortic valve thickness was significantly decreased after 14 days of treatment. In addition, the treatment group showed significantly less extensive valve lesions than the control group as well as reduced aortic valve calcification. Results of the study were published in April 2008 in the British Journal of Pharmacology.

"We are very pleased to add this exciting new intellectual property to our growing portfolio of HDL therapies," said Jean-Louis Dasseux, Ph.D., M.B.A., president and CEO of Cerenis. "Currently, patients who suffer from severe AVS have no option other than surgical valve replacement. Even after newer, minimally invasive surgery, there are risks of valve wear and blood clots, requiring permanent treatment with blood thinners. Cerenis is grateful to Dr. Tardif and his team for their ground-breaking work, and we look forward to moving this very promising treatment approach for AVS into clinical development."

About Cerenis Therapeutics

Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases. Based on pioneering research conducted by the Cerenis team of world leaders in HDL therapy, the Company is pursuing a range of HDL product candidates that are positioned to represent major advances in patient care and significant commercial opportunities in the treatment of cardiovascular and metabolic diseases. Cerenis has operations in Ann Arbor, Michigan and Toulouse, France.

For further information please visit www.cerenis.com.


'/>"/>
SOURCE Cerenis Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
2. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
3. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
4. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
5. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
6. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
7. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
8. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
11. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):